- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
FDA Clears Investigational New Drug Application for Influenza Antiviral
Via Nova Therapeutics’ VNT-101 is an Influenza A nucleoprotein inhibitor.
Via Nova Therapeutics announced that FDA has cleared its investigational new drug application for VNT-101.
The new therapy is a novel investigational small molecule that is described as an Influenza A nucleoprotein inhibitor. In a press release, Via Nova states that VNT-101 demonstrated activity in vitro against a variety of flu strains, including seasonal influenza A and avian influenza H5N1 and H7N9.
In the press release, Via Nova Therapeutics Ceo and co-founder Don Ganem, M.D., said, “We look forward to evaluating VNT-101 in the clinic. This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."
Source
(Sept. 21, 2023); PR Newswire; Via Nova Therapeutics Announces FDA Clearance of Investigational New Drug Application for VNT-101, A Novel Direct-Acting Antiviral Against Influenza A Virus; https://www.prnewswire.com/news-releases/via-nova-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-vnt-101-a-novel-direct-acting-antiviral-against-influenza-a-virus-301934192.html?tc=eml_cleartime
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
